Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 233 participants.
Also called NCT04365400
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 233 participants
- Sponsor
- Afimmune
- Registry
-
NCT04365400 -
2020-000065-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Georgia, Germany, Israel, Latvia, Switzerland
- Registry status
- Terminated
Technical summary
Registry record NCT04365400. Randomized; double masking; primary purpose treatment. Start 2020-10-13 (actual); primary completion 2022-05-03 (actual). Results posted on 2023-06-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
- Acronym
- TRIAGE
- Condition
- Hypertriglyceridemia
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- DS102
- Intervention (Drug)
- Placebo
- Lead sponsor
- Afimmune
Record details
- Record id
cardio:ct-nct04365400- Content hash
abef57b324f85366cf234e51dc8df8b101a28059d84b679b210e140bfc43f005